SCHEMBL31161295

SCHEMBL31161295

O=Cc1cnc(-c2cccc3c2CCN3)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.37
▸ S1PR3 Q99500 1/20 0.37
▸ P2RX7 Q99572 2/20 0.35
▸ HTR5A P47898 1/20 0.34
▸ PARP10 Q53GL7 3/20 0.34
▸ PARP11 Q9NR21 3/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ BCHE P06276 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC8 Q9BY41 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ HDAC5 Q9UQL6 1/20 0.32
▸ KDM1A O60341 1/20 0.32
▸ MAPKAPK2 P49137 1/20 0.32
▸ NUDT1 P36639 1/20 0.32
▸ CYP19A1 P11511 2/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ CYP11B1 P15538 1/20 0.32
▸ CYP11B2 P19099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31161874 0.85 PARP10 (0.32) PARP10PARP11
SCHEMBL31161543 0.85 PARP10 (0.32) PARP10PARP11
SCHEMBL31161725 0.80 S1PR1 (0.42) S1PR1S1PR3PARP10PARP11PARP1
SCHEMBL31161709 0.78 S1PR1 (0.36) S1PR1S1PR3PARP10PARP11PARP1
SCHEMBL31161954 0.78 S1PR1 (0.36) S1PR1S1PR3PARP10PARP11PARP1
SCHEMBL31162087 0.76 S1PR1 (0.35) S1PR1S1PR3HTR5ABCHEACHE
SCHEMBL31218654 0.75 S1PR1 (0.36) S1PR1S1PR3PARP10PARP11PARP1
SCHEMBL31161276 0.70 S1PR1 (0.36) S1PR1S1PR3PARP10PARP11PARP1
Trifluoroacetic Acid SCHEMBL26097973 0.70 HDAC1 (0.34) S1PR1S1PR3PARP10PARP11PARP1
SCHEMBL20539302 0.69 NOTUM (0.47) S1PR1S1PR3PARP10PARP11PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 S1PR1 3629/4885S1PR3 3749/4885P2RX7 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback